


AMENDMENT TO THE CLAIMS

Claims 1-15. (Cancelled)

Claim 16. (Newly presented) A conjugate or fusion protein of formula:



wherein A is a protein or polypeptide which binds specifically to a target cell surface, B is bis-maleimide polyethylene oxide and binds to both A and (C)_n, C is an MHC/peptide complex, and n is a whole number ranging from 1 to 10.

Claim 17. (Newly presented) The conjugate of claim 16, wherein A is an antibody or a binding fragment of an antibody.

Claim 18. (Newly presented) The conjugate of claim 17, wherein A is an Fab' fragment of an antibody.

Claim 19. (Newly presented) The conjugate of claim 16, wherein A is a single chain antibody.

Claim 20. (Newly presented) The conjugate of claim 18, wherein C is a single chain MHC complex.

Claim 21. (Newly presented) The conjugate of claim 19, wherein C is a single chain MHC complex.

Claim 22. (Newly presented) The conjugate of claim 16, wherein A is an antibody, a ligand which binds to an antigen, or a ligand which binds to a differentiation marker overexpressed in tumor cells.

- Claim 23. (Newly presented) The conjugate of claim 16, wherein said MHC molecule comprises a tumor rejection antigen.
- Claim 24. (Newly presented) The conjugate of claim 16, wherein said MHC molecule comprises an antigenic, viral peptide.